Joanne L Billings

Projects

Projects per year 2001 2011 2012 2013 2015 2018 2019 2021 2026

• 12 Active
• 49 Finished

Projects per year

Search results

• Women's Health in Cystic Fibrosis

  Billings, J. L.

  National Heart, Lung, and Blood Institute

  7/5/01 → 6/30/08

  Project: Research project

  • Women's Health 100%
  • Cystic Fibrosis 92%

• CF Therapeutics Development Network

  Billings, J. L.

  Cystic Fibrosis Foundation

  11/1/02 → 12/31/08

  Project: Research project

  • Network Development 100%

• A Phase III, Open-label, Follow-on Study of Multiple Cou

  Billings, J. L.

  Gilead Sciences, Inc.

  8/1/05 → 7/31/08

  Project: Research project

  • Aztreonam 100%
  • Cystic Fibrosis 71%
  • Inhalation 68%

• MULTIDOSE SAFETY AND TOLERABILITY STUDY OF LIPOSOMAL AMI

  Billings, J. L.

  TRANSAVE INC

  10/25/07 → 12/31/09

  Project: Research project

  • Amikacin 100%
  • Safety 98%
  • Inhalation 78%

• A Phase I/II Randomized, Double-Blind, Placebo-Controlle

  Billings, J. L.

  KaloBios Pharmaceuticals, Inc.

  11/14/07 → 12/31/09

  Project: Research project

  • Placebos 100%
  • Pseudomonas aeruginosa 67%

• Expanded Access Program for Aztreonam Lysine

  Billings, J. L.

  Gilead Sciences, Inc.

  1/15/08 → 12/31/10

  Project: Research project

  • Lysine 100%
  • Aztreonam 70%
  • Pseudomonas Infections 63%
  • Cystic Fibrosis 50%
  • Inhalation 47%

• A Phase 2, Multi-Center, Randomized, Double-Blind, Place

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  9/1/08 → 8/31/10

  Project: Research project

  • MP regimen 100%
  • Cystic Fibrosis 45%
  • Inhalation 43%
  • Placebos 31%
  • Safety 26%

• A Double-Blind, Multicenter, Multinational, Randomized,

  Billings, J. L.

  Gilead Sciences, Inc.

  10/1/08 → 9/30/09

  Project: Research project

  • Aztreonam 100%
  • Cystic Fibrosis 71%
  • Lysine 71%
  • Inhalation 68%
  • Lung Diseases 65%

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled,

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  9/16/09 → 9/9/12

  Project: Research project

  • Placebos 81%
  • Cystic Fibrosis 57%
  • Safety 34%
  • Mutation 33%

• A PHASE 3, MULTI-CENTER, MULTINATIONAL, RANDOMIZED, DOUB

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  2/10/11 → 12/31/12

  Project: Research project

  • Levofloxacin 100%
  • Cystic Fibrosis 80%
  • Inhalation 76%
  • Placebos 56%
  • Safety 47%

• A Phase 3, Open-Label, Randomized Trial To Evaluate The

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  3/15/11 → 6/1/13

  Project: Research project

  • Inhalation 100%
  • Cystic Fibrosis 52%
  • Safety 31%

• A Prospective, 5-year Registry Study to Monitor

  Billings, J. L.

  Gilead Sciences, Inc.

  7/1/11 → 7/1/17

  Project: Research project

  • Registries 100%
  • Aztreonam 86%
  • Cystic Fibrosis 61%
  • Pseudomonas aeruginosa 58%

• Early Intervention in Cystic Fibrosis Exacerbation (eICE

  Billings, J. L.

  Seattle Children's Hospital

  8/1/11 → 2/28/16

  Project: Research project

  • Cystic Fibrosis 100%

• G551D Observational Study

  Billings, J. L.

  Seattle Children's Hospital

  9/1/11 → 12/31/20

  Project: Research project

  • Observational Studies 100%

• A Phase 3, Open-Label, Randomized Trial To Evaluate The

  Billings, J. L.

  MPEX PHARMACEUTICALS, INC.

  3/15/12 → 3/14/13

  Project: Research project

  • Inhalation 100%
  • Cystic Fibrosis 52%
  • Safety 31%

• Prospective Observational Study to Evaluate Biomarkers

  Billings, J. L. & Dunitz, J. M.

  FOUNDATION FOR THE NAT'L INST. OF HEALTH

  4/1/12 → 6/30/16

  Project: Research project

  • Biomarkers 100%
  • Observational Studies 59%
  • Prospective Studies 48%
  • Safety 44%
  • Kidney 41%

• KB001A-05, A Phase 2, Randomized, Double-blind, Placebo-

  Billings, J. L.

  KaloBios Pharmaceuticals, Inc.

  11/30/12 → 6/30/15

  Project: Research project

  • Placebos 100%
  • Cystic Fibrosis 70%
  • Pseudomonas aeruginosa 67%

• Genetic Epidemiology of COPD

  Billings, J. L.

  National Jewish Health

  1/1/13 → 7/31/22

  Project: Research project

  • Molecular Epidemiology 100%
  • Chronic Obstructive Pulmonary Disease 75%

• A Phase 1b, Randomized, Double-Blind, Placebo-Controlled

  Billings, J. L.

  NIVALIS THERAPEUTICS, INC.

  1/15/13 → 1/15/15

  Project: Research project

  • N6022 100%
  • Placebos 62%
  • Cystic Fibrosis 44%
  • Pharmacokinetics 34%
  • Safety 26%

• A Phase 3, Randomized, Double Blind, Placebo Controlled,

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  1/31/13 → 1/31/16

  Project: Research project

  • lumacaftor 100%
  • Placebos 75%
  • Safety 31%

• A Phase 2, Multi-Center, Randomized, Placebo-Controlled

  Billings, J. L.

  Seattle Children's Hospital

  9/1/13 → 6/30/18

  Project: Research project

  • gallium nitrate 100%
  • Placebos 79%
  • Cystic Fibrosis 56%

• The EPIC Observational Study: Longitudinal Assessment of

  Billings, J. L.

  Seattle Children's Hospital

  9/1/13 → 10/1/20

  Project: Research project

  • Observational Studies 100%
  • Pseudomonas aeruginosa 59%
  • Child 27%
  • Therapeutics 10%

• VX12-809-105: A Phase 3, Rollover Study to Evaluate

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  12/6/13 → 12/6/16

  Project: Research project

  • lumacaftor 100%
  • Cystic Fibrosis 53%
  • Safety 31%

• A Two-Part Multicenter Prospective Longitudinal Study

  Billings, J. L.

  Seattle Children's Hospital

  7/1/14 → 1/31/19

  Project: Research project

  • Longitudinal Studies 100%
  • Prospective Studies 76%
  • Cystic Fibrosis 58%

• DMP-CF-303: Long Term Administration of Inhaled Mannitol

  Billings, J. L.

  PHARMAXIS LTD

  10/1/14 → 10/1/17

  Project: Research project

  • Mannitol 100%
  • Cystic Fibrosis 85%
  • Safety 25%

• 2015 Therapeutics Development Center Spring Meeting

  Billings, J. L.

  Cystic Fibrosis Foundation

  1/1/15 → 6/30/15

  Project: Research project

• University of Minnesota Additional Research Coordinator

  Billings, J. L.

  Cystic Fibrosis Foundation

  1/1/15 → 3/31/22

  Project: Research project

• A Phase 1b, Randomized, Double-Blind, Placebo-Controlled

  Billings, J. L.

  NIVALIS THERAPEUTICS, INC.

  1/31/15 → 1/31/17

  Project: Research project

  • cavosonstat 100%
  • Placebos 55%
  • Cystic Fibrosis 39%
  • Pharmacokinetics 30%
  • Safety 23%

• A Phase 3 Efficacy and Safety Study of Ataluren (PTC124)

  Billings, J. L.

  PTC Therapeutics, Inc.

  3/20/15 → 3/20/16

  Project: Research project

  • ataluren 100%
  • Safety 15%
  • Nonsense Codon 15%
  • Cystic Fibrosis 13%

• N91115-2CF-05 (SNO-6): A Phase 2, Randomized, Double-Bli

  Billings, J. L.

  NIVALIS THERAPEUTICS, INC.

  9/15/15 → 12/31/16

  Project: Research project

  • cavosonstat 100%
  • Cystic Fibrosis 13%
  • Placebos 9%

• VX14-661-110: A Phase 3, Open-label, Rollover Study to E

  Billings, J. L. & Laguna, T.

  Vertex Pharmaceuticals Incorporated

  10/5/15 → 10/5/18

  Project: Research project

  • tezacaftor 100%
  • Safety 27%

• Multicenter Clinical Phenotyping of Cystic Fibrosis

  Billings, J. L.

  University of California at San Diego

  12/1/15 → 11/13/17

  Project: Research project

  • Cystic Fibrosis 100%

• VX15-371-101: A Phase 2a, Randomized, Double-blind

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  12/15/15 → 5/31/18

  Project: Research project

  • VX 100%
  • Cystic Fibrosis 62%
  • Cross-Over Studies 57%
  • Placebos 43%
  • Safety 37%

• Nurse Practitioner Additional Research Coordinator(ARC)

  Billings, J. L.

  Cystic Fibrosis Foundation

  1/1/16 → 3/31/22

  Project: Research project

  • nurse 100%

• GS-US-404-1808: A Phase 2b, Dose-Ranging Study of the Ef

  Billings, J. L.

  Gilead Sciences, Inc.

  11/1/16 → 11/1/20

  Project: Research project

  • Cystic Fibrosis 42%

• VX15-440-101: A Phase 2, Randomized, Double-blind, Contr

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  11/6/16 → 1/1/20

  Project: Research project

  • VX 100%
  • Cystic Fibrosis 62%
  • Safety 37%
  • Therapeutics 10%

• Novartis CQBW276X2201: A randomized, double blind, place

  Billings, J. L.

  NOVARTIS PHARMACEUTICALS CORPORATION

  6/1/17 → 1/11/20

  Project: Research project

  • Cystic Fibrosis 100%
  • Pharmacokinetics 77%
  • Placebos 70%
  • Safety 59%

• VX16-809-120: A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety ofOrkambi in US Patients Who Completed Study VX12-809-105 Part A

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  4/1/18 → 12/31/19

  Project: Research project

  • ivacaftor drug combination lumacaftor 100%
  • Observational Studies 83%
  • Safety 62%

• VX17-659-102: A Phase 3, Randomized, Double-blind, Contr

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  4/12/18 → 3/12/20

  Project: Research project

  • VX-659 100%
  • Mutation 43%
  • Cystic Fibrosis 37%
  • Safety 22%
  • Therapeutics 6%

• VX17-659-105: A Phase 3, Open-label Study Evaluating the

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  5/9/18 → 5/1/21

  Project: Research project

  • VX-659 100%
  • Cystic Fibrosis 37%
  • Safety 22%
  • Mutation 21%
  • Therapeutics 6%

• PTI-808-01: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 inHealthy Adult Subjects and in Adults with Cystic Fibrosis

  Billings, J. L.

  PROTEOSTASIS THERAPEUTICS, INC.

  7/1/18 → 1/1/21

  Project: Research project

  • Cystic Fibrosis 100%
  • Pharmacokinetics 77%
  • Safety 59%
  • Healthy Volunteers 34%

• PTI-428-06: A Phase 2, Multicenter, Randomized, Double-Blind,Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 inSubjects with Cystic Fibrosis

  Billings, J. L.

  PROTEOSTASIS THERAPEUTICS, INC.

  9/28/18 → 1/1/20

  Project: Research project

  • Cystic Fibrosis 100%
  • Pharmacokinetics 77%
  • Placebos 70%
  • Safety 59%

• APPLAUD: A double-blinded, randomized, placebo-controlled, Phase 2 study of the efficacy and safety ofLAU-7B in the treatment of cystic fibrosis through correction of the AA/DHA imbalance

  Billings, J. L.

  LAURENT PHARMACEUTICALS INC

  11/1/18 → 10/31/21

  Project: Research project

  • Cystic Fibrosis 100%
  • Placebos 70%
  • Safety 59%
  • Therapeutics 16%

• A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacyof VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  3/21/19 → 1/1/21

  Project: Research project

  • VX 100%
  • Cystic Fibrosis 62%
  • Safety 37%
  • Therapeutics 10%

• Sexual and Reproductive Health in Adult Women with Cystic Fibrosis

  Billings, J. L.

  University of Pittsburgh

  4/1/19 → 3/31/20

  Project: Research project

  • Sexual Health 100%
  • Reproductive Health 99%
  • Cystic Fibrosis 83%

• A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safetyof 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508delMutation and a Gating or Residual Function Mutation (F/G and F/RF Ge

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  5/23/19 → 1/1/21

  Project: Research project

  • Cystic Fibrosis 99%
  • Mutation 85%
  • Safety 29%
  • Therapeutics 16%

• A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects aged 18 Years and Olderwith Cystic Fibrosis

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  6/1/19 → 7/31/22

  Project: Research project

  • VX 100%
  • Cystic Fibrosis 62%
  • Safety 37%

• A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  7/30/19 → 8/1/22

  Project: Research project

  • VX-445 100%
  • Mutation 44%
  • Cystic Fibrosis 39%
  • Genotype 28%
  • Safety 23%

• A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis

  Billings, J. L.

  Vertex Pharmaceuticals Incorporated

  7/30/19 → 7/30/22

  Project: Research project

  • VX-445 100%
  • Cystic Fibrosis 39%
  • Safety 23%
  • Therapeutics 6%